AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

In both adults with and without self-reported COPD, a 6- or 12-week course of cytisinicline helped more daily smokers achieve ...

Please provide your email address to receive an email when new articles are posted on . Data were derived from Baldomero AK, et al. JAMA Netw Open. 2025;doi:10.1001 ...